Richard Jon Barry
CEO, President & DirectorMr. Richard Jon Barry, also known as Rick, served as Independent Director at Filana Therapeutics, Inc. (formerly known as Cassava Sciences, Inc.) since June 11, 2021, until July 17, 2024 and served as its Executive Chairman of the Board since July 17, 2024 until September 2024 and serves as its CEO & Director since September 2024. He serves as President of Filana Therapeutics, Inc. (formerly known as Cassava Sciences, Inc.)from September 6, 2024. Mr. Barry Founded Eastbourne Capital Management, L.L.C. Mr. Barry has been a Partner and Advisory Board member of the San Diego Padres since 2009 and an Advisory Board Member for the Schreyer Honors College at Pennsylvania State University since 2014. He is a Managing Member of GSM Fund, LLC. Mr. Barry served as Managing General Partner, Managing Member and Portfolio Manager at Eastbourne Capital Management, L.L.C. from 1999 to its close in 2010. Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC. Mr. Barry spent over many years in various roles in institutional equity and investment management firms, including Lazard Freres, Legg Mason and Merrill Lynch. Prior to founding Eastbourne in 1999, Mr. Barry served with Robertson Stephens Investment Management from September 1995 to March 1999, as Portfolio Manager for the hedge funds and Managing Director. From 1992 to 1995, he served as an Analyst at Banyan Securities, where Mr. Barry provided in-depth equity research primarily for hedge funds. He worked at Regal Asset Management as a Portfolio Manager and an Analyst at the Feshbach Brothers. From 1982 to 1990, Mr. Barry worked in the brokerage industry, starting as a Retail Account Executive with Merrill Lynch. He served as a Vice President of Institutional Sales with Lazard Freres in New York. He spent two years as a Research Analyst at the Senate of Pennsylvania. He serves as a Director at NaZura BioHealth, Inc. He served as Independent Director of MiMedx Group, Inc. since June 19, 2019 until August 2020. He had been a Non-Employee Director at Sarepta Therapeutics, Inc. since June 2015 till March 2020. Mr. Barry served as a Director of Elcelyx Therapeutics, Inc since February 14, 2013 until 2019. He served as a Director of BlackLight Power Inc. since 2009 until 2010. He previously served as a Director of Cluster Wireless from 2011 until 2014. He graduated, Magna Cum Laude, with a BA in Political Science from Pennsylvania State University.
Positions
- Company NameFilana Therapeutics, Inc.Stock CodeFLNAPositionCEO, President & DirectorColleagues
- RJRichard Jon BarryCEO, President & Director
- CNClaude NicaiseIndependent Chairman
- EJEric J. SchoenChief Financial Officer
- RCR. Christopher CookChief Operating & Legal Officer
- GTGeorge ThorntonSenior Vice President of Technology
- MZMichael ZamlootSenior Vice President of Technical Operations
- PGPierre GravierIndependent Director
- RERobert Eugene AndersonIndependent Director
- GLGrant L. SchoenhardMember of Scientific Advisory Board
- Company NameSarepta Therapeutics, Inc.Stock CodeSRPTPositionIndependent DirectorColleagues
- IMIan Michael EstepanPresident & COO
- MKM. Kathleen Behrens WilseyIndependent Chairwoman
- RHRyan H. WongExecutive VP & CFO
- CLCristin L. RothfussExecutive VP, General Counsel & Company Secretary
- DSDouglas S. IngramAdvisor
- LRLouise R. Rodino-KlapacPresident of Research & Development and Technical Operations
- MEMichael E. SeverinoCEO & Director
- HWHans WigzellChairman of Corporate Strategy Board & Independent Non-Employee Director
- DPDeirdre P. ConnellyIndependent Director
